Tutorial in biostatistics: The self-controlled case series method

Statistics in Medicine

Volumn 25, Issue 10, 2006, Pages 1768-1797

  Whitaker, Heather J ^a   Farrington, C Paddy ^a   Spiessens, Bart ^b   Musonda, Patrick ^a  

^a OPEN UNIVERSITY   (United Kingdom)

^b GSK   (Belgium)

Author keywords

Case series; Conditional likehood; Control; Epidemiology; Modelling; Proportional incidence

Indexed keywords

ANTIDEPRESSANT AGENT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE;

ARTICLE; ASEPTIC MENINGITIS; ASTHMA; AUTISM; BACTERIAL INFECTION; BELL PALSY; BIOSTATISTICS; CASE STUDY; COVARIANCE; DRUG EXPOSURE; DRUG SAFETY; FEBRILE CONVULSION; GAIT DISORDER; HEART INFARCTION; HIP FRACTURE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; INTUSSUSCEPTION; MEASLES VACCINATION; MEDICAL RECORD; METHODOLOGY; OUTCOMES RESEARCH; RISK ASSESSMENT; STATISTICAL ANALYSIS; VIRUS MENINGITIS; WHEEZING;

BIOMETRY; CHILD, PRESCHOOL; DATA INTERPRETATION, STATISTICAL; HUMANS; INFANT; INTUSSUSCEPTION; MEASLES-MUMPS-RUBELLA VACCINE; MENINGITIS, VIRAL; MODELS, BIOLOGICAL; MODELS, STATISTICAL; POLIOVIRUS VACCINE, ORAL; PURPURA, THROMBOCYTOPENIC; RISK; VACCINATION;

EID: 33646790167     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2302     Document Type: Article

References (41)

1. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995; 51:228-235.
2. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology 1996; 143:1165-1173 (Erratum 1998; 147:93).
3. Miller E, Goldacre M, Pugh S, Colville A, Farrington CP, Flower A, Nash J, MacFarlane L, Tettmar R. Risk of aseptic meningitis after measles, mumps and rubellavaccine in U.K. children. Lancet 1993; 341: 979-982.
4. Farrington CP, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, Rush M, Miller E. A new method for active surveillance of adverse events from diphtheria tetanus pertussis and measles mumps rubella vaccines. Lancet 1995; 345:567-569.
5. Aalen OO, Borgan O, Keiding N, Thorman J. Interaction between life history events, non-parametric analysis for prospective and retrospective data in the presence of censoring. Scandinavian Journal of Statistics 1980; 7:161-171.
6. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986; 73:1-11.
7. Maclure M. The case-cross-over design: a method for studying transient effects on the risk of acute events. American Journal of Epidemiology 1991; 133(2):144-153.
8. Greenland S. A unified approach to the analysis if case-distribution (case-only) studies. Statistics in Medicine 1996; 18:1-15.
9. Maclure M, Mittleman MA. Should we use a case-cross-over design? Annual Review of Public Health 2000; 21:193-221.
10. Vines SK, Farrington CP. Within-subject exposure dependency in case-cross-over studies. Statistics in Medicine 2001; 20:3039-3049.
11. Feldmann U. Epidemiologic assessment of risks of adverse reactions associated with intermittent exposure. Biometrics 1993; 49:419-428.
12. Feldmann U. Design and analysis of drug safety studies, with special reference to sporadic drug use and acute adverse reactions. Journal of Clinical Epidemiology 1993; 46:237-244.
13. Miller E, Waight P, Farrington P, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood 2001; 84:227-229.
14. Dourado I, Cunha S, Teixeira M de G, Farrington CP, Melo A, Lucena R, Barreto ML. An outbreak of aseptic meningitis associated with a Urabe-containing MMR mass vaccination campaign: implications for immunization programs. American Journal of Epidemiology 2000; 151:524-530.
15. Taylor B, Miller E, Farrington CP, Petropoulos M-C, Favot-Mayaud I, Li J, Waight PA. Autism and measles, mumps and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353: 2026-2029.
16. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001; 19:3632-3635.
17. Miller E, Andrews N, Waight P, Taylor B. Bacterial infections, immune overload, and MMR vaccine. Archives of Disease in Childhood 2003; 88:222-223.
18. Miller E, Andrews N, Grant A, Stowe J, Toylor B. No evidence of an association between MMR vaccine and gait disturbance. Archives of Disease in Childhood 2005; 90:292-296.
19. Kramarz P, DeStefano F, Garguillo PM, Davis RL, Chen RT, Mullooly JP, Black SB, Shinefield MD, Bohlke K, Ward JI, Marcy MS. Does influenza vaccination exacerbate asthma? Archives of Family Medicine 2000; 9:617-623.
20. Tata LJ, West J, Harrison T, Farrington P, Smith C, Hubbard R. Does influenza vaccination increase consultations, corticosteroid prescriptions or exacerbations in people with asthma or chronic obstructive pulmonary disease? Thorax 2003; 58:835-839.
21. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of bell's palsy in Switzerland. New England Journal of Medicine 2004; 350: 896-903.
22. Andrews N, Miller E, Waight P, Farrington CP, Crowcroft N, Stowe J, Taylor B. Does oral polio vaccine cause intussusception in infants? Evidence from a sequence of three self-controlled case series studies in the United Kingdom. European Journal of Epidemiology 2001; 17:701-706.
23. Galindo Sardiñas MA, Zambrano Cárdenas A, Coutin Marie G, Santin Peña M, Aliño Santiago M, Valcárcel Sanchez M, Farrington CP. Lack of association between intussusception and oral polio vaccine in Cuban children. European Journal of Epidemiology 2001; 17:783-787.
24. Murphy TV, Garguillo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, Zanardi LR, Setia S, Fair E, LeBaron CW, Wharton M, Livingood JR. Intussusception among infants given an oral rotavirus vaccine. New England Journal of Medicine 2001; 344:564-572.
25. Mullooly JP, Pearson J, Drew L, Schuler R, Maher J, Gargiullo P, De Stefano F, Chen R and the vaccine safety datalink working group. Wheezing lower respiratory disease and vaccination of full-term infants. Pharmacoepidemiology and Drug Safety 2002; 11:21-30.
26. Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. American Journal of Epidemiology 2003; 158: 77-84.
27. Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, Hubbard R. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antodepressants on the risk of acture myocardial infarction. Heart 2005; 91:465-471.
28. Becker NG, Li Z, Kelman CW. The effect of transient exposures on the risk of an acute illness with low hazard rate. Biostatistics 2004; 5(2):239-248.
29. France EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR, Zangwill KM, Marcy SM, Mullooly JP, Jackson LA, Chen R. Safety of the trivalent inactivated influenza vaccine among children - a population based study. Archives of Pediatrics and Adolescent Medicine 2004; 158:1031-1036.
30. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. New England Journal of Medicine 2004; 351:2611-2618
31. Andrews NJ. Statistical assessment of the association between vaccination and rare adverse events post licensure. Vaccine 2002; 20:S49-S53.
32. Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 2004; 22:2064-2070.
33. Navidi W. Bidirectional case-cross-over designs for exposures with time trends. Biometrics 1998; 54(2): 596-605.
34. Lumley T, Levy D. Bias in the case-cross-over design: implications for studies of air pollution. Environmetrics 2000; 11:689-704.
35. Farrington CP, Whitaker HJ. Semi-parametric analysis of case series data. 2004, submitted.
36. StataCorp. Stata Statistical Software: Release 8.0. College Station, TX, STATA Corporation, 2003.
37. SAS 8. SAS Institute Inc. Cary, NC, U.S.A., 1999.
38. GenStat release 7.1. VSN International Ltd: Oxford, U.K., 2003.
39. GLIM release 4. Royal Statistical Society: London, U.K., 1992.
40. Payne RW (ed). The Guide to GenStat Release 7.1. Part 2: Statistics. VSN International: Oxford, U.K., 2003; 555-556.
41. Musonda P, Farrington CP, Whitaker HJ. Sample size formulae for the self-controlled case series method, in preparation.